I read with great interest the article by Lobaugh et al1 in the April 2001 issue of the ARCHIVES. I recently published 2 original articles on aberrations in intermediary metabolism and the effects of a peptide therapy on partially trisomic Ts65Dn mice, an animal model for Down syndrome. I am familiar with the claims of various Down syndrome advocacy groups on the use of the drug piracetam and with various nutritional intervention strategies to address health issues associated with this genetic disorder. Finally, I was also interviewed and quoted in 2 of the 3 American Broadcasting Corporation programs in which piracetam was discussed.
Croom J. Piracetam Study: Poorly Designed and Misinterpreted. Arch Pediatr Adolesc Med. 2001;155(10):1175-1176. doi:10.1001/archpedi.155.10.1175